OncLive On Air

We traveled to Chicago, Illinois, for a State of the Science Summit™ on Breast Cancer, where faculty provided a comprehensive look into present and potentially future standards of care in early-stage and advanced breast cancer subtypes.

We traveled to Washington, D.C., for a State of the Science Summit™ on Gastrointestinal Cancer, which focused on the clinically diverse and steadily expanding therapeutic armamentariums for patients with gastrointestinal malignancies.

We traveled to Kansas City, Missouri, for a State of the Science Summit™ on Hematologic Malignancies, which provided a comprehensive snapshot of the pivotal data that were presented at the 2018 ASH Annual Meeting.

Mario M. Leitao Jr, MD, FACOG, FACS, and Dmitriy Zamarin, MD, PhD, of Memorial Sloan Kettering Cancer Center, to discuss two common clinical scenarios faced in practice, and the data to support their approaches.

We traveled to Houston, Texas, for a State of the Science Summit™ on Gastrointestinal Cancer, which focused on the rapidly evolving landscapes of colorectal cancer, gastric/GEJ cancer, pancreatic cancer, neuroendocrine tumors, and hepatocellular carcinoma.

We traveled to Nashville, Tennessee, for a State of the Science Summit™ on Breast Cancer, which focused on some of the practice-changing updates that have been occurring in the field.

In keeping up with the rapidly changing landscape of gastroesophageal junction cancer, we sat down with Joseph Chao, MD, to discuss a clinical scenario he faced in practice, and how he used the latest data available to inform his treatment for his patient.

We traveled to Pasadena, California, for a State of the Science Summit™ on Genitourinary Malignancies, which focused on the rapidly evolving landscapes of kidney, bladder, and prostate cancer.

We sat down with Marwan Fakih, MD, a professor in the Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations at the Comprehensive Cancer Center, to discuss a clinical scenario he faced in practice, and how he used the latest data available to inform his treatment for his patient.

We traveled to Boston, Massachusetts, for a State of the Science Summit™ on Ovarian Cancer and Soft Tissue Sarcoma, which focused on the facets of genetic testing in ovarian cancer, surgical options available for patients with newly diagnosed disease, and emerging strategies for the treatment of patients with uterine sarcomas, among other key topics.